Comparison the effect of Olanzapine and Haloperidol on the treatment of delirium in ICU in Valiasr hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N114

Enrollment

Registered

2019-07-03

Start date

2019-01-05

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: Intervention group 1: We inject Haloperidol 2/5 milligram (maximum 40 milligram) intramuscular injection every 6 hours. Intervention 2: Intervention group 2: We inject 2/5 to 10 millig

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Delirium detection Age older than 18 years No pregnancy and breastfeeding Insensitivity to Olanzapine and Haloperidol Absence of QTC is greater than 440 milliseconds Absence of a neurological disease such as stroke, dementia, psychosis Having a urine catheter Lack of mental disorder or disability disorder pre-admission

Exclusion criteria

Exclusion criteria: Patients who have more than 24 hours of coma and have a structural reason for their low level of consciousness. Dissatisfaction

Design outcomes

Primary

Measure	Time frame
Sedation. Timepoint: Every 8 hours. Method of measurement: Richmond agitation and sedation scale.;Illness severity. Timepoint: In first and third day after the intervention. Method of measurement: APACHE II score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alireza Kamali

Arak University of Medical Sciences

alikamaliir@yahoo.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026